SBFM
NasdaqSUNSHINE BIOPHARMA INC.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$228,426
2021
$4.3M
2022
$24.1M
2023
$34.9M
2024
$36.3M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$36.3M
Net Income$-6.0M
Gross Profit$12.3M
Oper Income$-6.2M
EPS (dil)$-7.32
Rev/sh$7.25
FCF/sh$-1.10
Book/sh$4.60
Gross M33.8%
Oper M-17.2%
Profit M-16.5%
FCF M-15.2%
ROE-25.9%
ROA-19.9%
ROIC-39.1%
R&D/Rev1.7%
Rev Y/Y4.1%
Rev 3Y CAGR102.9%
EPS Y/Y97.9%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+5371.7%
Current Ratio4.17
Quick Ratio2.08
Debt/Eq0.09
Int Coverage—
Net Debt$7.1M cash
Total Debt$2.1M
Cash & Eq$9.1M
Total Assets$30.1M
Oper CF$-5.3M
Capex$174,491
Free CF$-5.5M
Buybacks$0
Equity$23.0M
Liabilities$7.0M
Shs Outstand0.01B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $228,426 | $4.3M | $24.1M | $34.9M | $36.3M |
| Gross Profit | $110,596 | $1.7M | $8.3M | $10.7M | $12.3M |
| Operating Income | $-2.4M | $-27.0M | $-4.8M | $-5.8M | $-6.2M |
| Net Income | $-12.5M | $-26.7M | $-4.5M | $-5.1M | $-6.0M |
| Diluted EPS | $-4.76 | $-1.76 | $-351.36 | $-7.32 | — |
| Operating Cash Flow | $-1.8M | $-5.2M | $-8.8M | $-12.5M | $-5.3M |
| Free Cash Flow | $-1.8M | $-5.4M | $-8.9M | $-14.2M | $-5.5M |
COMMUNITY · $SBFM0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.